COPP protocol

05/01/1993 - "C-MOPP/ABV yields good results in a public hospital population with Hodgkin disease in Brazil."
04/12/1996 - "The risk for gonadal toxicity in patients with Hodgkin's disease was related to the use of procarbacine as a part of the COPP-regimen and to infradiaphragmatic radiotherapy. "
01/01/1993 - "We analysed the effect of chemotherapy dose reductions on survival in 35 patients with Hodgkin's disease stage IIIB or IV treated at our institution by three double courses of C-MOPP/ABVD chemotherapy followed by either one further course or by involved-field radiotherapy. "
09/01/1992 - "In stage III and IV Hodgkin's disease, for example, an age-adjusted COPP regimen may be adopted. "
03/01/1990 - "Twenty two children, under 15 years of age, from southern Chile's Tenth Region, with advanced stages of Hodgkin's disease (8 III-A, 6 III-B and 8 IV-B) were treated with chemotherapy (modified COPP protocol) and radiotherapy between 1976 and 1985 at Valdivia's Regional Hospital. "

01/01/1991 - "Our results indicate that ProMACE-C-MOPP is an effective regimen for intermediate-grade lymphomas. "
07/01/1988 - "[Studies of patients with non-Hodgkin's lymphoma unresponsive to C-MOPP]."
01/01/2011 - "C-MOPP is a chemotherapy regimen for the treatment of Non-Hodgkin lymphoma (NHL). "
01/01/1991 - "ProMACE-C-MOPP in aggressive non-Hodgkin's lymphoma. "
06/01/1987 - "[C-MOPP therapy in advanced diffuse lymphoma, large cell type (LSG)]."

09/01/1976 - "Such good results with the COPP regimen in malignant histiocytosis have not been reported previously, and it is suggested that this modality of treatment warrants further trial."

03/01/1985 - "Studies conducted at the NCI demonstrated that 47% of all patients with advanced stages of diffuse mixed, large cell, and undifferentiated non-Burkitt's lymphoma could achieve a complete remission documented by reevaluation of all initially involved sites following treatment with either the C-MOPP or BACOP combination chemotherapy regimens. "

09/01/1979 - "The improved survival in the lymphocyte-like and fusiform categories accounted for most of our improved overall median survival rates with the COPP regimen in small cell lung cancer. "
01/01/1984 - "The COPP regimen (cyclophosphamide, Oncovin, procarbazine, prednisone) was one of the first chemotherapy programs to prolong survival in small cell lung cancer (SCLC) significantly. "